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Purpose: We studied changes in gene transcription after corneal crosslinking (CXL) in
the rabbit cornea in vivo and identified potential molecular signaling pathways.
Methods: A total of 15 corneas of eight male New-Zealand-White rabbits were de-
epithelialized and equally divided into five groups. Group 1 served as an untreated
control. Groups 2 to 5 were soaked with 0.1% riboflavin for 20 minutes, which in
Groups 3 to 5 was followed by UV-A irradiation at a fluence of 5.4 J/cm2. Ultraviolet A
(UVA) irradiation was delivered at 3 mW/cm2 for 30 minutes (Group 3, standard CXL
protocol), 9 mW/cm2 for 10 minutes (Group 4, accelerated), and 18 mW/cm2 for 5
minutes (Group 5, accelerated). At 1 week after treatment, corneal buttons were
obtained; mRNA was extracted and subjected to cDNA sequencing (RNA-seq).
Results: A total of 297 differentially transcribed genes were identified after CXL
treatment. CXL downregulated extracellular matrix components (collagen types 1A1,
1A2, 6A2, 11A1, keratocan, fibromodulin) and upregulated glycan biosynthesis and
proteoglycan glycosylation (GALNT 3, 7, and 8, B3GALT2). Also, CXL activated
pathways related to protein crosslinking (transglutaminase 2 and 6). In 9.1% of the
significantly different genes, CXL at 3 mW/cm2 (Group 1) induced a more distinct
change in gene transcription than the accelerated CXL protocols, which induced a
lower biomechanical stiffening effect.
Conclusions: Several target genes have been identified that might be related to the
biomechanical stability and shape of the cornea. Stiffening-dependent differential
gene transcription suggests the activation of mechano-sensitive pathways.
Translational Relevance: A better understanding of the molecular mechanisms
behind CXL will permit an optimization and individualization of the clinical treatment
protocol.
Introduction
Until recently, corneal ectasia could not be treated
and typically required corneal transplantation, in-
volving the risks of infection, protracted wound
healing, and rejection. In 1997, Spoerl et al.1 proposed
a new technique to increase the biomechanical
stiffness of the cornea: corneal crosslinking (CXL).
The treatment involves de-epithelialization of the
cornea, soaking the corneal stroma with a chromo-
phore (Vitamin B2, riboflavin), and ultraviolet A
(UVA) irradiation with 3 mW/cm2 for an additional
30 minutes. Multiple studies have shown that CXL
successfully stops keratoconus2 progression and also
arrests postsurgical corneal ectasia.3 Since its intro-
duction, a number of modifications of the original
treatment protocol have been proposed, aiming at
increasing its efficacy, shortening treatment duration,
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and reducing the risk of postoperative complications.
The most widely used modified treatment protocol is
accelerated CXL,4 using a higher irradiance in
combination with a shorter irradiation time. Howev-
er, several studies showed a reduced treatment
efficacy. In clinical settings, a shallower demarcation
line5–7 and minor corneal flattening7,8 was reported
with accelerated CXL compared to standard CXL; in
experimental settings, a lower tensile elastic modu-
lus9,10 and a lower dry-weight after enzymatic
digestion11 were found. Further modified treatment
protocols include iontophoresis-assisted,12 trans-epi-
thelial,13 hypo-osmolar,14 pulsed,15 contact lens–
assisted,16 and customized17 CXL. All modified
protocols share limited success: the increase in corneal
stiffness is lower compared to that of the standard
CXL treatment. A reason why it is difficult to
optimize CXL is that its working principle is poorly
understood. Although most mechanical strengthening
would be expected if bonds were formed between
collagen lamellae, x-ray scattering experiments indi-
cate that bonds are formed rather at the collagen fibril
surface and in the protein network surrounding the
collagen.18 Also, the corneal swelling capacity is
reduced strongly after CXL,19 suggesting that pro-
teoglycans and glycosaminoglycans are involved.20,21
Clinical trials currently are performed to address the
question whether CXL has the potential for primary
refractive corrections of myopia22 and hyperopia. A
better understanding of the basic mechanisms behind
CXL would allow better adaptation of the protocol
for different therapies, but also to identify its
limitations.
One might speculate that the arrest of keratoco-
nus progression induced by CXL implies long-term
and permanent changes on transcriptional, transla-
tional, and/or posttranslational levels. This hypoth-
esis is supported by the fact that the increase in
corneal stiffness after CXL lasts23 potentially longer
than the actual collagen turnover in the corneal
tissue and that significant—sometimes even progres-
sive—corneal flattening is observed after CXL
treatment.24 There are different mechanisms of how
CXL may change gene transcription: the generation
of large amounts of reactive oxygen species (ROS)
may activate signaling pathways25,26 with the poten-
tial of reintroducing homeostasis. Another mecha-
nism may involve mechanotransduction,27,28 which
means the process of converting mechanical signals
into biochemical responses. Mechanical signals may
result from dynamically acting forces, but also from
remodeling of the extracellular matrix (ECM),
leading to changes in cell adhesion and cell–cell
contact that finally determine the mechanical inter-
action with the surrounding matrix.29,30 Different
mechanisms of action have been identified for
mechanotransduction: certain ion-channels open in
response to increased tension in the plasma mem-
brane (observed during osmotic changes), proteins
can unfold domains upon tension that reveal cryptic-
binding, and phosphorylation may increase upon
stretching.27 These immediate changes may activate
signaling pathways and/or gene transcription within
minutes to hours.27,30,31
The purpose of this study was to analyze the
corneal transcriptome before and after CXL treat-
ment to identify differentially transcribed candidate
genes that potentially affect corneal stiffness.
Methods
Eight New Zealand White rabbits (2.5 kg weight)
were purchased from Charles River Laboratories
(Saint-Germaine-Nuelles, France). All experiments
were approved by the local ethical committee and
adhered to the ARVO Statement for the Use of
Animals in Ophthalmic and Visual Research.
CXL Treatment Protocol
Rabbits were anesthetized with a subcutaneous
injection of ketamine (Ketalar; Pfizer AG, Zurich,
Switzerland) and xylazine (Rompun 2%, 20 mg ml-1;
Bayer, Basel, Switzerland). A total of 15 eyes then
were assigned to one of five treatment groups (n ¼ 3
per group). The corneas of all groups were de-
epithelialized. Group 1 served as untreated control.
Groups 2 to 5 corneas additionally received 0.1%
riboflavin instillation during 20 minutes, using a
suction ring. Group 2 served as riboflavin control.
Group 3 corneas subsequently were irradiated with 3
mW/cm2 during 30 minutes, Group 4 corneas with 9
mW/cm2 during 10 minutes, and Group 5 corneas
with 18 mW/cm2 during 5 minutes. Riboflavin was
not renewed during UV irradiation. Three different
irradiances were included to study the effect of
different degrees of biomechanical stiffening.10 Di-
rectly after treatment, antibiotic ointment (Ofloxacin,
Floxal 0.3%; Bausch & Lomb, Zug, Switzerland) was
administered prophylactically onto the cornea and
repeated twice daily (until epithelial closure on
postoperative days 3–4) to avoid infections. In
addition, buprenorphin (Temgesic) was administered
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subcutaneously twice daily at 50 lg/kg until epithelial
closure.
Sample Preparation
One week after CXL treatment the rabbits were
sacrificed (intravenous 120 mg/kg, Pentothal; Ospe-
dalia AG, Hu¨nenberg, Switzerland) and the corneas
obtained with a trephine (8 mm diameter). The
corneal tissue was immersed in RLT lysis buffer þ
1% b-mercaptoethanol and homogenized, first with
scissors and then with a tissue disruptor (Qiagen
GmbH, Hilden, Germany). Afterwards, samples were
frozen in liquid nitrogen and stored at 808C.
Then, mRNA of the entire cornea, including
epithelial, keratocyte, and endothelial cells, was
extracted using an RNeasy kit (Qiagen) according to
the manufacturer’s instructions. mRNA quantity and
quality were assessed with a spectrophotometer (Qbit;
Life Technologies, Carlsbad, CA, USA) and the
Agilent 2100 bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA), respectively.
Differential Gene Transcription
Equal amounts of mRNA (300 ng) were reverse
transcribed, then cDNA sequencing (RNAseq) was
performed with the HighSeq 2500 system (Illumina,
San Diego, CA, USA) using the TruSeq stranded
mRNA protocol with 100 single-end reads. The
sequencing quality was controlled with FastQC
v.0.11.2 leading to a Phred quality score of .28
corresponding to a 1/1000 chance of errors. TopHat
v2.0.13 software was used for mapping against the
reference genome. The alignment percentage was
not optimal (~65%), probably due to low sequenc-
ing quality of the rabbit genome. As a consequence,
multiple-mapping reads were not considered in the
counts. Here, counts corresponded to the total
number of reads aligning to a genomic feature.
Biological quality control and summarization were
done with RSeQC v2.4 and PicardTools v1.92
software, respectively. Only genes with a count
above 10 in at least three samples were included for
further analysis. The normalization and differential
transcription analysis was performed with the R/
Bioconductor package edgeR v.3.10.5, for the genes
annotated in the reference genome.
Statistical Analysis
Differentially transcribed genes were determined
for each individual treatment group using a General
Linear Model (GLM), a negative binomial distribu-
tion and a quasi-likelihood test. Ten pairwise
comparisons (edgeR, GLM, quasi-likelihood F test)
of the experimental groups were analyzed (Table 1).
Instead of correcting the P values of the differentially
transcribed genes with the Bonferroni method for
multiple testing error, a different approach was
chosen selecting significant genes according to the
response of the whole set of CXL and control
conditions. For this purpose, a composite null
hypothesis, H0, was created summarizing the five
most important comparisons. The condition CXL at
18 mW/cm2 was excluded in this selection process, as
its treatment efficacy is smallest, as shown experi-
mentally9–11 and clinically5–8 and, hence, its meaning-
fulness is lower than the other comparisons.
H0 ¼ Hvirgin¼3mW Hvirgin¼9mW
 Hribo¼3mW Hribo¼9mWj j
;Hvirgin¼ribo ð1Þ
and hence:
H1 ¼ ;H0
¼ ;Hvirgin¼3mW & ;Hvirgin¼9mW & ;Hribo¼3mW &
;Hribo¼9mW &Hvirgin¼ribo ð2Þ
where H1 is the composite null hypothesis. Hx¼y
represents an individual null hypothesis, that is there
is no difference between x and y. ~Hx¼y represent a
rejected null hypothesis, that is there is a difference
between x and y. Each comparison between CXL (at 3
or 9 mW/cm2) and control (virgin or riboflavin) is
expected to be significant. In contrast, the comparison
between the two control conditions is expected not to
be significant. A given gene then will be considered
significant, if H1 is true. With a confidence interval of
95%, the probability for a false positive in one
comparison is:
Pi ¼ Pvirgin ;¼3mW
   Pvirgin ;¼9mW
   Pribo ;¼3mWð Þ
 Pribo ;¼9mWð Þ  Pribo¼virgin
 
ð3Þ
The probability of Pribo¼virgin cannot be calculated
exactly, as it is the power of the test. However,
assuming that the power is 1, we have neglected this
term resulting in Pi  0.054. Applied to the entire set
of n¼ 9335 analyzed genes, the probability of having
at least one false-positive can be calculated:
Pcumulative ¼ 1  1  Pið Þn  0:0567 ð4Þ
This P value, Pcumulative, is comparable to the
standard significance level. An alternative correc-
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tion for multiple testing is the Bonferroni method,
which, however, can be applied only to one group
at a time. The above-described whole-data-set ap-
proach is superior, as it accounts for the reprodu-
cibility of the CXL effect before correcting for
multiple testing. Figure 1 illustrates that with Bon-
ferroni correction, lower statistical significance (19
significantly different genes) can be reached than
Table 1. Differential Gene Transcription was Computed for a Total of 10 Comparisons Between Different
Treatment and Control Groups
Comparison Between Groups
# Significant Genes,
at 5% FDR þ FC  2
# Downregulated,
FC  2
# Upregulated,
FC  2
Riboflavin vs. virgin 2 1 1
CXL 3 mW 30 min vs. virgin 504 201 303
CXL 9 mW 10 min vs. virgin 18 10 8
CXL 18 mW 5 min vs. virgin 4 0 4
CXL 3 mW 30 min vs. riboflavin 862 341 521
CXL 9 mW 10 min vs. riboflavin 36 19 17
CXL 18 mW 5 min vs. riboflavin 1 1 0
CXL 9 mW 10 min vs. CXL 3 mW 30 min 161 93 68
CXL 18 mW 5 min vs. CXL 3 mW 30 min 165 88 77
CXL 18 mW 5 min vs. CXL 9 mW 10 min 0 0 0
Figure 1. Comparison of different approaches to correct for multiple statistical testing. (A) Bonferroni method resulting in 19
significantly differently transcribed genes. (B) Whole-data-set method developed in this manuscript resulting in 297 significantly
differently transcribed genes.
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with the whole-data-set approach (297 significantly
different genes).
Filter for Stiffening Dependent Gene
Transcription
The resulting list of significantly transcribed genes
then was subjected to filtering to determine genes that
are transcribed differentially in a stiffening-dependent
manner. The following criteria Filter(stiffening) was
imposed:
C1 ¼ logFCvirgin3mW.0
 
& logFCvirgin9mW.0
 
& logFCvirgin18mW.0
 
& logFCribo3mW.0ð Þ
& logFCribo9mW.0ð Þ& logFCribo18mW.0ð Þ
& logFC3mW9mW, 0ð Þ& logFC3mW18mW, 0ð Þ
& logFC9mW18mW, 0ð Þ ð5aÞ
C2 ¼ logFCvirgin3mW, 0
 
& logFCvirgin9mW, 0
 
& logFCvirgin18mW, 0
 
& logFCribo3mW, 0ð Þ
& logFCribo9mW, 0ð Þ& logFCribo18mW, 0ð Þ
& logFC3mW9mW.0ð Þ& logFC3mW18mW.0ð Þ
& logFC9mW18mW.0ð Þ ð5bÞ
FilterðstiffeningÞ ¼ H1& ;H3mW¼9mW& ;H3mW¼18mW
& C1jC2ð Þ ð5cÞ
where logFC is the fold-change in log2 scale between
the different tested conditions; & and j represent the
logical operators AND and OR, respectively.
Correlation Analysis
The Pearson’s linear correlation coefficient among
all treatment conditions was calculated for selected
differentially transcribed genes using Matlab software
(Mathworks, Bern, Switzerland) to investigate mutual
gene interactions. The online tool DAVID32,33 Bio-
informatics Resources (Version 6.8) was used to
extract related signaling pathways.
Results
Differential Gene Transcription
From a total of 9335 transcripts, 297 were
significantly differentially transcribed between the
two clinically efficient CXL conditions (at 3 and 9
mW/cm2) and controls (virgin and riboflavin). Of
these differentially transcribed genes, 9.1% (27 genes)
were significantly stiffening-dependent, as per the
definition above.
Most of the 297 differently transcribed genes were
related to signaling (42), disulfide bonding (34),
nucleotide binding (26), ATP binding (21), hydrolase
(19), transferase (17), secreted (14), DNA binding
(14), extracellular matrix (8), DNA replication (8),
immunoglobulin domain (6), helicase (5), tyrosine
protein kinase (5), collagen (3), DNA repair (3), and
DNA damage (3). Figure 2 presents a subset of
pathways and genes that are likely involved in corneal
mechanical properties.
Stiffening-dependent and -independent
Differentially Transcribed Genes
Table 2 and Supplementary Table S1 present genes
that were significantly differentially transcribed in a
stiffening-dependent and stiffening-independent man-
ner, respectively. Several genes of either subset have
been reported previously to show an altered gene
expression in keratoconus (references provided in the
Tables).
Figure 3 shows the change in normalized counts of
selected genes for the different treatment and control
conditions: Enzymatic crosslinking by transglutamin-
ases 2 and 6 was increased significantly after CXL
(Figs. 3A, 3B). Also, the expression of polypeptide N-
acetylgalactosaminyltransferase 3 and b-1,3-galacto-
syltransferase 2, both related to the glycosylation of
proteoglycans, was increased in crosslinked corneas
(Figs. 3C, 3D). The only collagen type that was
significantly upregulated after CXL was type IV,
which forms part of the basement membrane. All
other collagen types (I, VI, XI) were downregulated
(Figs. 3E–H). Downregulation also was observed in
noncollagenous ECM components, including throm-
bosponding 4 and keratocan (Figs. 3I, 3J). At the
same time, enzymatic glycolysis by means of enolase 1
and transketolase was reduced in crosslinked corneas
(Figs. 3K, 3L).
Most Affected Signaling Pathways after CXL
Treatment
Table 3 presents the two most affected pathways.
Seven genes of the ECM receptor interaction pathway
and 19 genes of the glycan biosynthesis and metab-
olism pathway were significantly differentially tran-
scribed.
Correlation analysis
Figure 4 shows genes that strongly correlated
(cpearson.0.8, P . 0.05) with thrombospondin 4, a
matricellular protein that is involved in tissue
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remodeling. Among its highest correlated genes were
structural extracellular matrix components, including
collagen (types I, II, VI, XI), keratocan, and
fibromodulin.
Discussion
We analyzed differential gene transcription in-
duced by CXL treatment and observed a significant
remodeling of the ECM, including changes in collagen
synthesis, glycan biosynthesis, and proteoglycan
glycosylation.
Fibrillar collagen types I and XI were downregu-
lated after CXL, while the epithelial basement
membrane constituting34 collagen type IV was upre-
gulated. Decreased collagen types I and XI transcrip-
tion potentially results from a reduced collagen
degradation after CXL, while increased collagen type
IV may be attributed to the recent re-epithelialization
and continuing epithelial remodeling.
The activity of enzymes related to glycosylation
(enolase 1, transketolase) and, hence, to ECM
degradation, was decreased after CXL treatment.
Previously, enolase 1 and transketolase overexpres-
sion had been reported in context with increased
ECM degradation and cancer invasion.35–37 Interest-
ingly, a reduced expression of enolase, transketolase,
and the protease inhibitor a2-macroglobulin-like 1
has been reported in keratoconus,38–46 which, how-
ever, was not able to prevent corneal ectasia.
In contrast, other genes were inversely differentially
transcribed after CXL treatment when compared to
Figure 2. Signaling pathways with specific genes that were significantly affected by CXL treatment and are likely to be involved in
corneal stiffness.
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keratoconus: collagen type I, keratocan, and throm-
bospondin 4 were downregulated after CXL, but
upregulated in keratoconus.41,47 These ECM compo-
nents potentially may be involved in extracellular
remodeling resulting from the increased corneal
stiffness after CXL. Thrombospondin 4 has been
identified previously as a mechano-sensing molecule
in the cardiac contractile response to mechanical stress
showing upregulation in response to hypertension.48
After CXL-treatment, the mechanical stress resistance
increases and, as a consequence, the tissue strain
decreases, which may have led to the downregulation
of thrombospondin 4. In the same line, in keratoconus,
where increased tissue strain in the cone region is
observed, an overexpression of thrombospondin 4 has
been reported. Further potential mechano-sensitive
genes may be involved in the molecular signaling after
CXL treatment (see Table 2), which in turn could
modify the transcription of nonmechano-sensitive
genes (see Supplementary Table S1).
Table 2. Genes that Were Significantly Differently Transcribed in a Stiffening-Dependent Manner
Gene
External
Name Chromosome Description
ENSOCUG00000006901 ANKRD1 18 Ankyrin repeat domain-containing protein 1
ENSOCUG00000011970 TAGLN 1 Transgelin
ENSOCUG00000008236 LPL 15 Lipoprotein lipase-like precursor
ENSOCUG00000026419 DHFR 11 Dihydrofolate Reductase
ENSOCUG00000003636 TGM2 4 Transglutaminase 2
ENSOCUG00000002632 KRT7 4 Keratin 7, type II
ENSOCUG00000012542 CACNA2D3 9 Calcium channel, voltage-dependent, alpha 2/delta
subunit 3
ENSOCUG00000014740 SLC37A2 1 Solute carrier family 37 (glucose-6-phosphate
transporter), member 2
ENSOCUG00000002272 MYH7B 4 Myosin, heavy chain 7B, cardiac muscle, beta
ENSOCUG00000017128 NMU 15 Neuromedin U
ENSOCUG00000015001 CYB5R2 1 Cytochrome b5 reductase 2
ENSOCUG00000011919 SEMA3A 10 Sema domain, immunoglobulin domain (Ig), short basic
domain, secreted, (semaphorin) 3A
ENSOCUG00000000023 PKP2 8 Plakophilin 2
ENSOCUG00000014012 A2ML1 8 Alpha-2-macroglobulin-like 1
ENSOCUG00000006999 C2 12 Complement component 2
ENSOCUG00000003876 FHDC1 15 FH2 domain containing 1
ENSOCUG00000017894 NFKBIE 12 Nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, epsilon
ENSOCUG00000001869 MUC21 12 Mucin 21, cell surface associated
ENSOCUG00000003858 GNMT 12 Glycine N-methyltransferase
ENSOCUG00000029530 CENPH 11 Centromere protein H
ENSOCUG00000027827 CXCL16 19 Chemokine (C-X-C motif) ligand 16
ENSOCUG00000001419 CSAD 4 Cysteine sulfinic acid decarboxylase
ENSOCUG00000005127 11 Uncharacterized protein
ENSOCUG00000014805 WNT3 19 Wingless-type MMTV integration site family, member 3
ENSOCUG00000015904 TKT 9 Transketolase
ENSOCUG00000010331 FAM92A1 3 Family with sequence similarity 92, member A1
ENSOCUG00000003862 DUT 17 Deoxyuridine triphosphatase
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One of the identified stiffening-independent mech-
anisms of CXL was the increase in enzymatic
proteoglycan glycosylation and glycan biosynthesis
(Table 3). b1,3-galactosyltransferase 2 is involved in
the N-acetyl-D-glucosamine sugar addition on the
keratan sulfate proteoglycan. A deficiency in a similar
enzyme, b1–4 galactosyltransferase 7, has been
associated with Ehlers-Danlos syndrome,49 which
manifests in joint hyperelasticity and previously also
has been reported in context with corneal curvature
abnormalities, including keratoconus, keratoglobus,
and cornea plana.50,51 These pathologies likely arise
from an alteration of corneal stiffness. Other condi-
tions that affect corneal stiffness include diabetes and
aging, in which nonenzymatic glycation is in-
creased.52,53 In contrast with increased enzymatic
glycosylation (as observed after CXL), increased
nonenzymatic glycation is a random process that
makes it less specific in ECM crosslinking.
Table 2. Extended
Average Normalized Counts SD Normalized Counts
Virgin Riboflavin 3 mW 9 mW 18 mW Virgin Riboflavin 3 mW 9 mW 18 mW
0.00 0.00 10.67 0.6667 0.3333 0.00 0.00 4.51 0.5774 0.5774
0.00 0.00 7.67 1.6667 1.3333 0.00 0.00 1.53 0.5774 0.5774
1.33 1.33 53.33 10.3333 7.6667 0.58 0.58 18.45 14.4684 4.7258
82.33 88.67 0.67 6.3333 14.3333 65.65 73.66 0.58 4.5092 12.5033
17.00 14.33 393.67 104.0000 36.0000 8.54 12.86 151.96 95.3939 28.4781
16.33 21.67 308.33 99.3333 91.6667 7.37 19.14 26.50 9.2376 57.8302
7.67 4.67 0.67 2.0000 2.0000 1.53 2.08 0.58 1.0000 1.0000
5.00 3.33 23.67 9.0000 9.3333 1.00 0.58 15.89 3.0000 1.5275
3.33 4.00 0.33 1.3333 1.6667 1.53 1.00 0.58 0.5774 1.1547
4.67 6.00 0.33 1.6667 3.0000 1.53 3.00 0.58 1.1547 2.6458
91.33 127.33 9.00 32.3333 64.3333 33.98 44.06 2.00 20.5508 19.6044
27.00 36.33 142.00 78.6667 73.6667 7.55 9.87 25.24 19.5533 30.6649
17.00 13.67 77.33 35.3333 27.6667 9.54 5.86 12.10 9.5044 9.0738
393.67 447.00 47.67 170.0000 199.6667 59.00 55.56 7.23 63.8357 109.9288
5.67 5.00 27.33 12.0000 9.0000 2.08 3.46 13.61 3.4641 3.6056
13.33 10.00 46.33 26.6667 23.3333 4.93 1.00 8.39 10.0664 7.7675
9.67 7.67 34.67 16.0000 13.3333 1.53 2.08 6.81 1.0000 4.0415
381.33 322.00 1126.67 680.6667 675.6667 119.78 133.63 174.95 19.2959 38.6566
73.67 111.00 19.67 39.3333 59.6667 24.66 55.22 1.53 19.5533 5.6862
17.00 21.67 5.67 10.0000 10.6667 6.00 3.79 1.53 1.0000 1.5275
14.00 14.00 45.00 23.0000 20.3333 3.00 5.29 5.29 1.7321 1.5275
114.33 118.33 45.33 65.0000 66.3333 16.29 18.45 6.66 8.7178 10.6927
87.67 101.67 35.33 54.6667 56.6667 9.29 14.01 16.04 1.5275 9.2916
91.33 103.00 31.33 59.6667 63.3333 26.63 18.52 3.51 10.2144 20.6478
10,385.67 9981.00 3718.33 6365.3333 7070.0000 1039.99 395.81 361.28 1185.9049 1477.5155
42.00 46.33 17.33 28.0000 34.3333 9.17 11.55 4.16 3.6056 2.0817
27.33 31.00 11.33 17.6667 24.0000 7.51 4.36 3.06 1.1547 4.5826
8 TVST j 2017 j Vol. 6 j No. 6 j Article 8
Kling et al.
Downloaded from tvst.arvojournals.org on 08/24/2020
Although the 18 mW/cm2 condition was excluded
to identify the significantly differentially transcribed
genes between crosslinked and control corneas, its
expression levels either were in a similar absolute
range as the 3 and 9 mW/cm2 conditions, or did
confirm the gradient between the 3 and 9 mW/cm2
conditions. This can be considered as an additional
quality control, but at the same time emphasizes the
fact that CXL protocols differ on the molecular level
in an irradiance/time dependent way.
In absence of an animal model of keratoconus,
we used healthy corneas in the experimental groups.
It remains to be investigated, if the identified
pathways differ in keratoconic corneas. Also, more
studies are needed to fully understand the interac-
tion between gene transcription and phenotypic
response after CXL. Although it would have been
interesting to validate the significantly transcribed
genes on the proteomic level, this aspect was out of
scope of this study given the high number of
Table 2. Extended
log10
(cum_P Value) Cum_logFC Remark
8.41 inf
11.03 inf Increased expression in keratoconus41
6.31 4.16
7.22 3.59
7.53 3.51 Increased expression in vitro after CXL treatment;43 catalyzes covalent
crosslinking e-(g-glutamyl) lysine bonds
8.25 3.13 Increased in keratoconus54
8.29 1.99
7.13 1.75 Involved in glycogenolysis and gluconeogenesis; channels excess sugar
phosphates to glycolysis in the pentose phosphate pathway
7.03 1.72
7.01 1.68
9.07 1.63
8.83 1.63
6.18 1.61
8.95 1.60 Decreased in keratoconus;45 inhibitor of several proteases
5.83 1.59
8.64 1.46
7.63 1.30
8.70 1.23
6.10 1.22 Involved in gluconeogenesis55
7.89 1.14
7.64 1.07
10.51 0.98
7.20 0.95
7.33 0.92
7.40 0.83 Decreased expression in keratoconus epithelium;42 involved in
glycosaminoglycan metabolism; disulfide as acceptor
7.46 0.73
7.29 0.72
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Figure 3. Changes in the normalized counts of transcription for selected genes: (A, B) related to enzymatic crosslinking, (C, D) related to
proteoglycan glycosylation, (E–H) structural ECM components, (I, J) other ECM components, and (K, L) related to ECM degradation.
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identified genes. A further limitation was that we
could not separate the differentially transcribed
genes according to their origin (keratocytes, epithe-
lial and endothelial cells). Therefore, the results
presented here describe the overall response of ECM
relevant differential transcription. Future studies
may address the individual contribution of kerato-
cytes and epithelial cells, as well as potential effects
on wound healing.
In summary, several target genes potentially
related to the biomechanical stability and shape of
the cornea were identified. Our findings suggest that
corneal stiffening after CXL likely results from a
decreased ECM degradation in combination with an
increased enzymatic glycosylation, and hence, an
altered proteoglycan interaction with collagen fibrils.
A proteoglycan-based stiffening after CXL also
would be in line with previous findings from x-ray
scattering.18
Table 3. Significantly Differentially Transcribed Genes of the Two Strongest Affected Pathways 1 Week After
CXL Treatment
Ensembl ID Gene Name Gene Cum_logFC
log10
(cum_P Value)
ECM receptor interaction
ENSOCUG00000012881 Collagen type I alpha 1 chain COL1A1 2.53 2.22
ENSOCUG00000009244 Thrombospondin 4 THBS4 2.39 3.79
ENSOCUG00000013367 Collagen type XI alpha 1 chain COL11A1 2.33 2.9
ENSOCUG00000012264 Collagen type I alpha 2 chain COL1A2 2.18 2.23
ENSOCUG00000000409 Collagen type VI alpha 2 chain COL6A2 2.06 1.78
ENSOCUG00000017726 Integrin subunit alpha 11 ITGA11 2.03 11.21
ENSOCUG00000013276 Collagen type IV alpha 2 chain COL4A2 2.01 2.95
Glycan biosynthesis and metabolism
ENSOCUG00000005127 Dihydrofolate reductase DHFR 3.59 7.22
ENSOCUG00000001596 Beta-1,3-galactosyltransferase 2 B3GALT2 2.42 3.3
ENSOCUG00000009557 Polypeptide
N-acetylgalactosaminyltransferase 8
GALNT8 2.29 6.9
ENSOCUG00000009957 Tyrosine aminotransferase TAT 1.58 3.89
ENSOCUG00000002336 Bone marrow stromal cell antigen 1 BST1 1.01 8.57
ENSOCUG00000001419 Cysteine sulfinic acid decarboxylase CSAD 0.98 10.51
ENSOCUG00000011080 Polypeptide
N-acetylgalactosaminyltransferase 7
GALNT7 0.94 3.57
ENSOCUG00000000356 Glucosylceramidase beta GBA 0.93 5.23
ENSOCUG00000010086 Enolase 1 ENO1 0.85 5.15
ENSOCUG00000008667 Thymidylate synthetase TYMS 0.85 9.52
ENSOCUG00000000006 Inositol polyphosphate-1-phosphatase INPP1 0.83 5.33
ENSOCUG00000015904 Transketolase TKT 0.83 7.4
ENSOCUG00000004762 Synaptojanin 2 SYNJ2 0.8 5.45
ENSOCUG00000010823 Phosphoribosylformylglycinamidine
synthase
PFAS 0.77 3.86
ENSOCUG00000003862 Deoxyuridine triphosphatase DUT 0.72 7.29
ENSOCUG00000013372 Ribonucleotide reductase catalytic
subunit M1
RRM1 0.69 9.62
ENSOCUG00000004957 Polypeptide
N-acetylgalactosaminyltransferase 3
GALNT3 0.54 2.24
ENSOCUG00000004221 Tyrosinase related protein 1 TYRP1 0.28 7.33
ENSOCUG00000028025 Ethanolamine kinase 2 ETNK2 0.24 4.35
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